866-997-4948(US-Canada Toll Free)

EC145 (Ovarian Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Ovarian Cancer

No. of Pages : 31 Pages

 

GlobalDatas pharmaceuticals report, EC145 (Ovarian Cancer) - Analysis and Forecasts to 2020 provides EC145 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of EC145 including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of EC145 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2016-2020 for EC145 in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 8


3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13


5 EC145 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.3.1 Phase III Study 16
5.3.2 Phase II Study 16
5.4 Approval Status of EC145 16
5.5 Factors Affecting Sales 17
5.5.1 Mechanism of Action 17
5.5.2 Efficacy and Safety Profile of EC145 17
5.5.3 Absence of Competition in the Third Line Treatment 17
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of Competition 18
5.7 Sales Forecasts 18
5.7.1 Target Patient Pool of EC145 18
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 19
5.7.5 Sales Projections of EC145 20


6 Ovarian Cancer Market: Appendix 27
6.1 Market Definitions 27
6.2 List of Abbreviations 27
6.3 Research Methodology 27
6.3.1 Coverage 27
6.3.2 Secondary Research 28
6.3.3 Forecasting 28
6.3.4 Number of Patients Approved to take the Drug 28
6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 30
6.3.8 Primary Research 30
6.3.9 Expert Panels 30
6.4 Contact Us 30
6.5 Disclaimer 30
6.6 Sources 31

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score of EC145 17
Table 5: Estimated Annual Cost of Therapy of EC145, 2016 19
Table 6: EC145, Ovarian Cancer, Global, Sales Forecasts ($m), 20162020 20
Table 7: EC145, Ovarian Cancer, The US, Sales Forecasts ($m), 20162020 21
Table 8: EC145, Ovarian Cancer, France, Sales Forecasts ($m), 20162020 22
Table 9: EC145, Ovarian Cancer, Germany, Sales Forecasts ($m), 20162020 23
Table 10: EC145, Ovarian Cancer, Italy, Sales Forecasts ($m), 20162020 24
Table 11: EC145, Ovarian Cancer, Spain, Sales Forecasts ($m), 20162020 25

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of EC145 18
Figure 9: EC145, Ovarian Cancer, Global, Sales Forecasts ($m), 20162020 20
Figure 10: EC145, Ovarian Cancer, The US, Sales Forecasts ($m), 20162020 21
Figure 11: EC145, Ovarian Cancer, France, Sales Forecasts ($m), 20162020 22
Figure 12: EC145, Ovarian Cancer, Germany, Sales Forecasts ($m), 20162020 23
Figure 13: EC145, Ovarian Cancer, Italy, Sales Forecasts ($m), 20162020 24
Figure 14: EC145, Ovarian Cancer, Spain, Sales Forecasts ($m), 20162020 25
Figure 15: EC145, Ovarian Cancer, Global, Sales Distribution (%), 2020 26
Figure 16: Drug Model Diagram 29
Figure 17: Patients Approved for the Drug 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *